companies developing glp-1 drugs India pharma develop versions of Wegovy to get in on weight-loss windfall The Next Big Weight Loss

The kidney in heart failure: an update

Williams RA, Roe LS, Rolls BJ

the trial emulation framework helps align determination of eligibility, treatment assignment, and the beginning of follow-up, reducing important sources of biasincluding immortal time bias (which arises when treatment strategies are defined after the start of follow-up) and selection bias (which arises when follow-up starts after treatment assignment).73 We used data from the US Department of Veterans Affairs which integrates information from multiple data streams including healthcare encounters (both inpatient and outpatient), diagnostic codes, laboratory test results, vital signs, medication use, sociodemographic data, and data on use of supportive and rehabilitation services

Besides this, increasing awareness of the advantages of these drugs through marketing efforts and direct-to-consumer advertising, particularly on social media, and a favorable regulatory landscape are enabling approvals and boosting demand in the market

Basis Di.s 1867 (7), 166133 (2021)

24,37 GLP-1 RAs have been associated with improved renal outcomes, including enhanced natriuresis and reduced albuminuria, which are beneficial in diabetic kidney disease